• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Precision Neuroscience uses BCI to enable real-time thought-based control of computers

Precision Neuroscience uses BCI to enable real-time thought-based control of computers

July 21, 2026 By Sean Whooley

Precision Neuroscience Layer 7 Array
[Image courtesy of Precision Neuroscience]
Precision Neuroscience announced today that it used its brain-computer interface (BCI) to enable real-time, thought based computer control.

The company says this feat makes it the first to enable such control without penetrating the brain. Activities achieved included making phone calls, sending messages and playing Mario Kart.

According to Precision, cursor control is widely recognized as a foundational milestone for BCI technology. In recent BCI developments, technology achieved this through access deep in the brain. For instance, Neuralink’s BCI implant achieved real-time cursor control. However, that system relies on electrodes penetrating the brain.

Precision Neuroscience develops the Layer 7 cortical interface system. The high-density, ultra-thin cortical electrode array enables BCI technology that aims to address paralysis. Using AI models, it translates brain activity into a code that can help inform motor function restoration.

Layer 7 features 1,024 electrodes embedded in a flexible film that conforms to the brain surface. It comes in at one-fifth the thickness of a human hair. This device aims to help users with severe paralysis operate digital devices, like computers and smartphones, using their thoughts.

The New York-based company won FDA clearance for Layer 7 in April 2025. It also partnered with Medtronic this year to further advance BCI technology.

Layer 7 sits on top of the brain, causing no damage to tissue. Now, Precision says its milestone proves that powerful BCI functionality is possible without penetrating the brain. The company says that, if these systems don’t damage the brain, they become much more scalable, accessible, and practical for a wide range of potential uses in the future.

Jayme Strauss, chief clinical officer at Precision Neuroscience, said:

“Our goal from day one has been to break down the walls of isolation that come with paralysis. By achieving real-time cursor control completely on the surface of the brain, we’ve proven that we don’t have to compromise safety to achieve high-performance results. This is a thrilling glimpse into the future of BCIs, and we are moving faster than ever to bring this technology to patients who need it most.”

Filed Under: Brain-Computer Interface (BCI), Clinical Trials, Featured, Health Technology, Implants, Neurological Tagged With: Precision Neuroscience

More recent news

  • Citi downgrades Boston Scientific as cyberattack recovery compounds competitive pressure
  • Autonomix taps former Medtronic FDA counsel head for board of directors
  • Medtronic strengthens robotic surgery position with Cornerstone deal, analysts say
  • Science Corp. names president as it looks to roll out vision-restoring implant
  • Mindray looks to fill hospital ventilator gap left by Philips’ exit

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy